Figure 8.Forest plots comparing acceptability of treatment discontinuation and QoL. (A) Treatment discontinuation; (B) QoL.
Figure 8 — Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis | Aging
